X4 Pharmaceuticals Risk Adjusted Performance
| XFOR Stock | | | USD 3.69 -0.19 -4.90% |
This technical indicator view for Risk Adjusted Performance organizes signals for X4 Pharmaceuticals and comparable instruments. Data availability can vary by region and feed;
Equity Screeners provides broader screening access. X4 Pharmaceuticals has a market cap of 322.64 M, operating margin of -12.81%, ROE of -1.57%. See
Your Current Watchlist for portfolio-level analysis. This suggests a position in X4 Pharmaceuticals inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in employment.
Ready to invest in XFOR Stock? Our
How to Invest in X4 Pharmaceuticals guide walks you through the process.
X4 Pharmaceuticals has current Risk Adjusted Performance of 0.0163.
RAP | = | (ER[a] - RFR) * STD[b])/STD[b]RFR |
| = | 0.0163 | |
X4 Pharmaceuticals Risk Adjusted Performance Peers Comparison
XFOR Risk Adjusted Performance Relative To Other Indicators
X4 Pharmaceuticals is ranked
fifth for risk adjusted performance against industry peers. It is currently under evaluation for maximum drawdown against industry peers with Maximum Drawdown measuring nearly
1,490 against Risk Adjusted Performance. Maximum Drawdown runs about
1,490 times Risk Adjusted Performance for X4 Pharmaceuticals
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.